A Monoclonal Antibody Against Transmissible Gastroenteritis Virus Generated via Immunization of a DNA Plasmid Bearing TGEV S1 Gene

Zhao, Qianqian; Zhu, Jiayi; Zhu, Wei; Li, Xunliang; Tao, Ye; Lv, Xiaonan; Wang, Handong; Yin, Jun; He, Cheng; Ren, Xiaofeng

doi:10.1089/mab.2012.0067

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronaviruses (CoVs) of late have been very common throughout the world and among the different types of CoVs, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) andthe Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been found to be most deadly of them all. A particular form of porcine coronavirus known as Transmissible gastroenteritis virus (TGEV) 68,69 had caused increased mortality in pigs and the vaccination to piglets provided protection to suckling piglets, however, on a larger scale, it did not promote enhancement of immunity and did not control the spread of the infection. 70,71 Hence the development of an alternative therapeutic strategy is imminent in the control of such an infection.…”

Section: Potential Of Silver Nanoparticles On Coronavirusesmentioning

confidence: 99%

Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)

Ghosh¹,

An²,

Hm³

et al. 2021

IJPER

View full text Add to dashboard Cite

Aim:The aims of this review are to assess the anti-viral and targeting strategies using nano materials and the possibility of using Silver nanoparticles for combating the SARS-CoV-2. Background: The novel Coronavirus (SARS-CoV-2) has become a global pandemic and has spread rapidly worldwide. Researchers have successfully identified the molecular structure of the novel coronavirus however significant success has not yet been observed with the therapies currently in clinical trials and exhaustive studies are yet to be carried out in the long road to discovery of a vaccine or a possible cure. Another hurdle associated with the discovery of a cure is the mutation of this virus which may occur at any point in time. Hypothesis: Previous studies have identified a wide number of strains of Coronaviruses with differences in virulent properties. Silver nanoparticles have been used extensively in anti-viral research with promising results in-vitro. However, it has not yet been tested for the same in clinical subjects. It has also been tested on two variants of coronavirus in-vitro with significant data to understand the pathogenesis and which may be implemented in further research possibly in other variants of coronavirus. Another interesting targeting approach would be to test the effect of Silver Nanoparticles on TNF-α as well as Interleukins in SARS-CoV-2 patients. Conclusion: Sufficient evidence is required for its therapeutic potential and it still has to go a long way in SARS-CoV-2 research.

show abstract

Section: Potential Of Silver Nanoparticles On Coronavirusesmentioning

confidence: 99%

Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)

Ghosh¹,

An²,

Hm³

et al. 2021

IJPER

View full text Add to dashboard Cite

show abstract

“…Particularly some coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the recently identified Middle East respiratory syndrome coronavirus (MERS-CoV) may cause fatal infection in human. Transmissible gastroenteritis virus (TGEV), a porcine coronavirus, causes very high mortality in piglets and thus has tremendous impact of pig industry [11,12]. Vaccination has been extensively applied to prevent pigs from TGEV infection.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections

et al. 2014

Self Cite

View full text Add to dashboard Cite

Coronaviruses belong to the family Coronaviridae, which primarily cause infection of the upper respiratory and gastrointestinal tract of hosts. Transmissible gastroenteritis virus (TGEV) is an economically significant coronavirus that can cause severe diarrhea in pigs. Silver nanomaterials (Ag NMs) have attracted great interests in recent years due to their excellent anti-microorganism properties. Herein, four representative Ag NMs including spherical Ag nanoparticles (Ag NPs, NM-300), two kinds of silver nanowires (XFJ011) and silver colloids (XFJ04) were selected to study their inhibitory effect on TGEV-induced host cell infection in vitro. Ag NPs were uniformly distributed, with particle sizes less than 20 nm by characterization of environmental scanning electron microscope and transmission electron microscope. Two types of silver nanowires were 60 nm and 400 nm in diameter, respectively. The average diameter of the silver colloids was approximately 10 nm. TGEV infection induced the occurring of apoptosis in swine testicle (ST) cells, down-regulated the expression of Bcl-2, up-regulated the expression of Bax, altered mitochondrial membrane potential, activated p38 MAPK signal pathway, and increased expression of p53 as evidenced by immunofluorescence assays, real-time PCR, flow cytometry and Western blot. Under non-toxic concentrations, Ag NPs and silver nanowires significantly diminished the infectivity of TGEV in ST cells. Moreover, further results showed that Ag NPs and silver nanowires decreased the number of apoptotic cells induced by TGEV through regulating p38/mitochondria-caspase-3 signaling pathway. Our data indicate that Ag NMs are effective in prevention of TGEV-mediated cell infection as a virucidal agent or as an inhibitor of viral entry and the present findings may provide new insights into antiviral therapy of coronaviruses.

show abstract

“…1) [4]. Previous studies have determined that the A site (which is fully dependent on glycosylation for proper folding) is predominantly responsible for stimulating neutralizing host antibodies [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein

Yuan

Lin

Fan

2015

Vaccine

View full text Add to dashboard Cite

To explore the possibility of developing a vaccine against transmissible gastroenteritis virus (TGEV) infection, a recombinant swinepox virus (rSPV-SA) expressing a TGEV protective antigen has been constructed. Immune responses and protection efficacy of the vaccination vector were assessed in both mice and pig models. An indirect ELISA assay suggested that when mice were vaccinated with rSPV-SA, the level of IgG against TGEV was enhanced dramatically. The cytokine assays were employed and the results indicated that both the Th1-type and Th2-type cytokine levels raised after vaccination with rSPV-SA in mice models. Results from the passive immunity protection test of new born piglets demonstrated that the recombinant live-vector vaccine, rSPV-SA, could 100% protect piglets from the SPV infection, and there was no significant clinical symptom in the rSPV-SA treatment group during this experiment. The data suggest that the novel recombinant swinepox virus is a potential vaccine against TGEV infection.

show abstract

A Monoclonal Antibody Against Transmissible Gastroenteritis Virus Generated via Immunization of a DNA Plasmid Bearing TGEV S1 Gene

Cited by 7 publications

References 16 publications

Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)

Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)

Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections

Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein

Contact Info

Product

Resources

About